Literature DB >> 1736889

Isolation of cleaved prolactin variants that stimulate DNA synthesis in specific cell types in rat pituitary cell aggregates in culture.

M Andries1, D Tilemans, C Denef.   

Abstract

Using an affinity column of monoclonal antibodies against rat prolactin (PRL), PRL immunoreactive material secreted by rat pituitary aggregate cell cultures was purified in milligram amounts from the culture medium. Further purification of the PRL immunoreactive molecules was achieved by anion-exchange and reversed-phase h.p.l.c. At least four variants could be distinguished which showed PRL-like bioactivity in the Nb2 lymphoma bioassay. On SDS/PAGE two variants migrated as single bands under both reducing and non-reducing conditions. The two other variants migrated as single bands under non-reducing conditions, but yielded under reducing conditions two fragments, the larger of which had molecular masses of approx. 16 and 17 kDa respectively. These variants were therefore considered to be cleaved PRL (clPRL) variants, and were designated clPRL-1 and clPRL-2 respectively. These variants were not artefactually produced at low pH during the h.p.l.c. purification step. Each of the clPRLs represented about 0.6-1.0% of total PRL. The cleavage site of clPRL-1, determined by N-terminal and C-terminal amino acid sequence analysis, was in the large disulphide loop between Tyr-145 and Leu-146. Purified clPRL-1 added to pituitary aggregate cell cultures from 14-day-old female rats in the presence of the dopamine agonist bromocriptine increased [3H]thymidine incorporation into DNA in gonadotrophs and thyrotrophs, but not in other pituitary cell types. Under the same experimental conditions the main forms of PRL and clPRL-2 were inactive. These data demonstrate that PRL is cleaved within the pituitary gland between specific amino acid residues, and that PRL cleaved between Tyr-145 and Leu-146 may have a specific biological role as a paracrine growth regulator in this tissue.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1736889      PMCID: PMC1130697          DOI: 10.1042/bj2810393

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  36 in total

1.  Selectivity of juxtaposition between cup-shaped lactotrophs and gonadotrophs from rat anterior pituitary in culture.

Authors:  W Allaerts; A Mignon; C Denef
Journal:  Cell Tissue Res       Date:  1991-02       Impact factor: 5.249

Review 2.  Structural features of prolactins and growth hormones that can be related to their biological properties.

Authors:  C S Nicoll; G L Mayer; S M Russell
Journal:  Endocr Rev       Date:  1986-05       Impact factor: 19.871

3.  Prolactin variants in the rat adenohypophysis.

Authors:  G N Shah; W C Hymer
Journal:  Mol Cell Endocrinol       Date:  1989-01       Impact factor: 4.102

4.  Regulatory activity and topological distribution of folliculo-stellate cells in rat anterior pituitary cell aggregates.

Authors:  W Allaerts; C Denef
Journal:  Neuroendocrinology       Date:  1989-04       Impact factor: 4.914

5.  Evidence for functional communication between folliculo-stellate cells and hormone-secreting cells in perifused anterior pituitary cell aggregates.

Authors:  M Baes; W Allaerts; C Denef
Journal:  Endocrinology       Date:  1987-02       Impact factor: 4.736

6.  Demonstration of biological activity of prolactin molecular weight variants in human sera.

Authors:  M D Whitaker; G G Klee; P C Kao; R V Randall; D W Heser
Journal:  J Clin Endocrinol Metab       Date:  1984-05       Impact factor: 5.958

7.  A cleaved form of prolactin in the mouse pituitary gland: identification and comparison of in vitro synthesis and release in strains with high and low incidences of mammary tumors.

Authors:  Y N Sinha; T A Gilligan
Journal:  Endocrinology       Date:  1984-06       Impact factor: 4.736

8.  Immunocytochemical and pharmacological evidence for an intrinsic cholinomimetic system modulating prolactin and growth hormone release in rat pituitary.

Authors:  P Carmeliet; C Denef
Journal:  Endocrinology       Date:  1988-08       Impact factor: 4.736

9.  Proteolytic fragmentation of rat prolactin by the rat ventral prostate gland.

Authors:  M M Compton; R J Witorsch
Journal:  Prostate       Date:  1983       Impact factor: 4.104

10.  Evidence for paracrine interaction between gonadotrophs and lactotrophs in pituitary cell aggregates.

Authors:  C Denef; M Andries
Journal:  Endocrinology       Date:  1983-03       Impact factor: 4.736

View more
  6 in total

Review 1.  Paracrinicity: the story of 30 years of cellular pituitary crosstalk.

Authors:  C Denef
Journal:  J Neuroendocrinol       Date:  2008-01       Impact factor: 3.627

2.  Immunoreactive prolactins of the neurohypophyseal system display actions characteristic of prolactin and 16K prolactin.

Authors:  F J López-Gómez; L Torner; S Mejía; G M de la Escalera; C Clapp
Journal:  Endocrine       Date:  1995-08       Impact factor: 3.633

Review 3.  Cleavage of prolactin by its target organs and the possible significance of this process.

Authors:  C S Nicoll
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-01       Impact factor: 2.673

4.  The prolactin gene is expressed in the hypothalamic-neurohypophyseal system and the protein is processed into a 14-kDa fragment with activity like 16-kDa prolactin.

Authors:  C Clapp; L Torner; G Gutiérrez-Ospina; E Alcántara; F J López-Gómez; M Nagano; P A Kelly; S Mejía; M A Morales; G Martínez de la Escalera
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-25       Impact factor: 11.205

5.  Bone morphogenetic protein 1 processes prolactin to a 17-kDa antiangiogenic factor.

Authors:  Gaoxiang Ge; Cecilia A Fernández; Marsha A Moses; Daniel S Greenspan
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-04       Impact factor: 11.205

6.  N-terminal prolactin-derived fragments, vasoinhibins, are proapoptoptic and antiproliferative in the anterior pituitary.

Authors:  Jimena Ferraris; Daniela Betiana Radl; Sandra Zárate; Gabriela Jaita; Guadalupe Eijo; Verónica Zaldivar; Carmen Clapp; Adriana Seilicovich; Daniel Pisera
Journal:  PLoS One       Date:  2011-07-07       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.